Heparin-induced thrombocytopenia

Slides:



Advertisements
Similar presentations
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia Jeanine M. Walenga,
Advertisements

HEPARIN INDUCED THROMBOCYTOPENIA GALILA ZAHER MBB ch, dip C Path, MRC Path.
Heparin-Induced Thrombocytopenia (HIT)
 Background  Cost  Benefit  Complication.
Heparin Binds Plasma Proteins: Angiomax ® (Bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules)
HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,
IS IT HIT OR HAT? M&M Conference 3/28/02. HAT Mild thrombocythopenia 100K- 130K Incidence: 25% 1-4 days after starting heparin Non immune-mediated (direct.
Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An Improved Definition of Immune Heparin-Induced.
MLAB Coagulation Keri Brophy-Martinez
Elvira Maličev Blood Transfusion Centre of Slovenia
Volume 134, Issue 1, Pages (July 2014)
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Detection of platelet- derived microparticles: An alternative strategy for the diagnosis of heparin-induced thrombocytopenia. François Mullier, N. Bailly,
Anesthes. 1997;87(3): Figure Legend:
HIT: The Consequences of Heparin’s Nonspecific Binding to Platelet Factor 4 Heparin is neutralized by platelet factor 4, (PF4), which is present in high.
Copyright © 1999 American Medical Association. All rights reserved.
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
Characteristics of High and Low Molecular Weight Heparin Chains
Coagulation Cascade of the Newborn
by Nadine Martel, James Lee, and Philip S. Wells
Triple play of H pylori in ITP
Polyphosphates rock! A role in thrombosis?
K. -M. Kaukonen, R. Linko, H. Herwald, L. Lindbom, E. Ruokonen, T
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,
Another Notch on the belt
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Inflammatory Reactivation and Angiogenicity of Kaposi’s Sarcoma-Associated Herpesvirus/HHV8: A Missing Link in the Pathogenesis of Acquired Immunodeficiency.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Heparin induced thrombocytopenia
Deep mining of the RBC proteome
Thrombosis in flowing blood
Taking a leaf from the book of oral tolerance
Theodore E. Warkentin, MD  The American Journal of Medicine 
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia by Lubica Rauova, Mortimer Poncz, Steven E.
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
ROCK and Rho(ll) in bone marrow
IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia
Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.
Apoptotic Vascular Endothelial Cells Become Procoagulant
Enzymes Biology.
How I treat catastrophic thrombotic syndromes
Heparin-Induced Thrombocytopenia in Patients with Ventricular Assist Devices: Are New Prevention Strategies Required?  Theodore E. Warkentin, MD, Andreas.
Enzyme-Substrate Complex
When is HIT Really HIT? The Annals of Thoracic Surgery
How I treat cancer-associated venous thromboembolism
Milton M. Slocum, MD, John G. Adams, MD, Rosemary Teel, MT, Donald P
The identification and management of heparin-induced thrombocytopenia in the vascular patient  Glenn M. LaMuraglia, MD, Rabih Houbballah, MD, Michael.
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu T. Kalathottukaren, A.
Denis Jullien, Jörg C. Prinz, Frank O. Nestle 
Enzymes Biology.
Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies by Grace M. Lee, Manali Joglekar, Maragatha Kuchibhatla, Sanjay Khandelwal,
Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery  Barbara A Konkle, MD, Thomas L Bauer, MD, Gowthami.
The von Willebrand Factor protein showing various functional domains that have been mapped to regions of the cDNA. The von Willebrand Factor protein showing.
Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution  Raymond G. Makhoul, M.D., Charles S. Greenberg,
Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia by Douglas B. Cines,
Section B: Science update
HUS and atypical HUS by T. Sakari Jokiranta Blood
Trousseau's syndrome: multiple definitions and multiple mechanisms
Rituximab immunotherapy: it’s getting personal
Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient 
How I treat heparin-induced thrombocytopenia and thrombosis
How I treat disseminated intravascular coagulation
Myeloproliferative neoplasms and thrombosis
RANK ligand and osteoprotegerin in myeloma bone disease
Presentation transcript:

Heparin-induced thrombocytopenia by Gowthami M. Arepally Blood Volume 129(21):2864-2872 May 25, 2017 ©2017 by American Society of Hematology

A time line of key clinical and laboratory-based observations in HIT A time line of key clinical and laboratory-based observations in HIT. Important clinical developments are provided above the time band, and major research observations are noted below. A time line of key clinical and laboratory-based observations in HIT. Important clinical developments are provided above the time band, and major research observations are noted below. DTI, direct thrombin inhibitor; HITT, HIT with thrombosis; SRA, serotonin release assay. Gowthami M. Arepally Blood 2017;129:2864-2872 ©2017 by American Society of Hematology

Importance of PF4/heparin ultralarge complexes (ULCs) in HIT pathogenesis. Importance of PF4/heparin ultralarge complexes (ULCs) in HIT pathogenesis. (A) PF4, a positively charged protein, binds to negatively charged heparin through electrostatic interactions to form ULCs that govern HIT biology. At concentrations of PF4 or heparin excess, repulsive forces from excess charge predominate and are not permissive for complex formation. At stoichiometric ratios associated with charge neutralization, ULCs form capable of biological effects associated with in vivo immunogenicity33 (B), differential clinical effects of UFH and LMWH31 (C), and heparin-dependent reactivity in laboratory assays19 (D). Gowthami M. Arepally Blood 2017;129:2864-2872 ©2017 by American Society of Hematology